Specialist in nuclear medicine and Head of the Department of Nuclear Medicine at Vienna General Hospital (AKH).
Dr. Marcus Hacker is a specialist in nuclear medicine with extensive clinical and scientific experience in molecular imaging using PET/CT diagnostics, as well as in radionuclide therapy for oncological diseases, particularly prostate cancer.
Since 2013, he has been Professor of Nuclear Medicine at the Medical University of Vienna, where he heads the University Clinic of Nuclear Medicine at Vienna General Hospital (AKH). In this role, he combines clinical excellence with university teaching and internationally recognised research.
A key focus of his work is the further development and clinical application of modern PET tracers and radiopharmaceuticals for oncological therapy, including PSMA-based procedures, as well as interdisciplinary collaboration with urology, oncology and other medical specialties. Dr. Hacker is the author and co-author of more than 500 scientific publications in renowned international journals and is regularly involved in national and international research projects.
At Theranosticum Vienna, Dr. Hacker contributes his many years of university and clinical expertise to precise reporting, medical assessment and evidence-based decision-making. His aim is to provide clear, structured diagnostics as the basis for comprehensible, individually tailored medical therapy recommendations.
Memberships
- Society of Nuclear Medicine and Molecular Imaging (SNMMI)
- European Association of Nuclear Medicine (EANM)
- American College of Cardiology
- Austrian Society of Nuclear Medicine
- Austrian Platform for Personalized Medicine
Languages
- German
- English
Professional Background
- Univ.-Prof. Dr. med. Marcus Hacker studied human medicine at FAU Erlangen-Nürnberg and Technical University of Munich and completed his training at the Department of Nuclear Medicine at Ludwig Maximilian University of Munich, where he received his doctorate in 2002.
- Following his specialist training and his habilitation in 2008, he was appointed Senior Consultant and Deputy Director of the department.
- Since 2013, he has been a University Professor of Nuclear Medicine at Medical University of Vienna and Head of the Clinical Division of Nuclear Medicine at Vienna General Hospital.
- From 2013 to 2017, he served as a board member and secretary of the German Society of Nuclear Medicine, and from 2016 to 2020, he was President of the Austrian Society of Nuclear Medicine.
- Prof. Hacker has held and continues to hold visiting professorships in Serbia, Bosnia and Herzegovina, as well as in Taiwan and Changsha, China, and has been Editor-in-Chief of the scientific journal EJNMMI Research since 2025.
- His scientific focus lies on theranostic applications, oncological and cardiovascular imaging, and the development of new radiopharmaceuticals; he is the author of more than 500 publications.
Publications
- Hacker M.
EJNMMI research: a vision for the next era of nuclear medicine.
EJNMMI Res. 2026 Mar 9;16(1):41. doi: 10.1186/s13550-026-01404-0.PMID: 41803415 - Geist BK, Guthrie J, Kertesz H, Kiefer FW, Kulterer OC, Nakuz T, Nics L, Patronas EM, Rendeiro A, Vraka C, Yu J, Grünert S, Hacker M.
The metabolic organ connectome: A novel approach to measure allostatic load during health-to-disease transition.
Med. 2025 Dec 12;6(12):100881. doi: 10.1016/j.medj.2025.100881. Epub 2025 Oct 14.PMID: 41092907 - Jiang Z, Spielvogel C, Haberl D, Yu J, Krisch M, Szakall S, Molnar P, Fillinger J, Horvath L, Renyi-Vamos F, Aigner C, Dome B, Lang C, Megyesfalvi Z, Kenner L, Hacker M.
Spatial imaging features derived from SUVmax location in resectable NSCLC are associated with tumor aggressiveness.
Eur J Nucl Med Mol Imaging. 2026 Feb;53(3):1458-1468. doi: 10.1007/s00259-025-07528-0. Epub 2025 Aug 21.PMID: 40839309 - Jiang Z, Haberl D, Spielvogel C, Szakall S, Molnar P, Yu J, Lungu V, Fillinger J, Renyi-Vamos F, Aigner C, Dome B, Lang C, Kenner L, Megyesfalvi Z, Hacker M.
Using 18F-FDG PET/CT-derived body composition features to predict lymphovascular invasion in non-small cell lung cancer.
Eur J Nucl Med Mol Imaging. 2026 Jan;53(2):774-785. doi: 10.1007/s00259-025-07435-4. Epub 2025 Jul 23.PMID: 40699302 - Schmitl S, Kretschmer-Chott E, Patronas EM, Kramer G, Ritt P, Fuchs E, Weisbrod M, Nics L, Mitterhauser M, Hacker M.
Efficacy, Safety, Blood Kinetics, and 213Bi Distribution Studies of [225Ac]Ac-SibuDAB in Prostate Cancer Patients.
J Nucl Med. 2025 Aug 1;66(8):1239-1244. doi: 10.2967/jnumed.125.269655.PMID: 40473466 - Kluge K, Haberl D, Haug A, Kenner L, Kramer G, Shariat S, Kumpf K, Hacker M.
Genomic instability is associated with response to [¹⁷⁷Lu]Lu-PSMA-I&T radioligand therapy: an exploratory, preliminary liquid biopsy analysis.
Eur J Nucl Med Mol Imaging. 2025 Sep;52(11):4151-4156. doi: 10.1007/s00259-025-07280-5. Epub 2025 Apr 22.PMID: 40261406 - Hacker M.
The bet on PET: detecting liver lesions is not enough.
Lancet Gastroenterol Hepatol. 2025 Apr;10(4):277-278. doi: 10.1016/S2468-1253(25)00023-8. Epub 2025 Feb 20.PMID: 39987938
“Many patients come to us with uncertainty. It is important to me that findings are not only medically accurate but also provide clear guidance. Good diagnostics should help patients better understand their situation and see the next steps more clearly.”
Dr. Marcus Hacker
We take time for what matters - your care
If you have questions or would like to schedule an appointment, we are here for you.
In a personal consultation, we discuss your concerns in a calm setting and outline the next steps together.
Our team will get back to you promptly and support you competently and reliably - from the first contact through to your therapy appointment.
